Daily FNArena News - Small Caps

All | Australia | Book Reviews | Commodities | ESG Focus | FYI | International | Small Caps | Technicals | Treasure Chest

Latest Stories

A disappointing update on recently acquired powercloud does not ruin the investment case for Hansen Technologies, analysts say

Feb 26 2024

While Data3#’s earnings result confirmed its January trading update, the market was not impressed with how profit growth was achieved

Feb 19 2024

Run-of-the-mill accounting software company Reckon may be set for a re-rating, brokers believe

Feb 15 2024

Artificial intelligence and some valuable experiences should benefit heart device developer Artrya, Tim Boreham explains

Feb 15 2024

Previous Stories

Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024

Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports

Judo Answers The Critics

Jan 24 2024

In response to a broker’s negative assessment, Judo Capital has provided a surprise trading update that significantly exceeded expectations

Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023

Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results

Dr Boreham’s Crucible: Imugene

Dec 11 2023

Tim Boreham highlights the prospects for cancer treatment biotech Imugene

Luxury Cars Still Selling For Autosports

Nov 28 2023

Despite higher interest rates, Autosports Group is seeing no easing in demand for luxury cars, providing solid revenue growth guidance at its AGM

Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023

Tim Boreham highlights how PYC Therapeutics’ gene therapy can address a plethora of genetic afflictions

Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023

Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising

Dropsuite Trajectory Impresses

Oct 25 2023

Already enthusiastic analysts have lifted their enthusiasm regarding Dropsuite’s outlook following impressive third quarter results

Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023

FDA approval for Cyclopharm’s device-as-a-drug is welcome news, Tim Boreham reports

ASX Seafood Sector Swimming Against The Tide

Oct 05 2023

The New Criterion’s Tim Boreham navigates the choppy seas of a fraught Australian seafood-farming market

Analyse The Market From A Different Angle